Hobson Prior’s Post

By joining the Pharmacovigilance Operations PEAK Matrix® assessment, you will spotlight your capabilities, gain visibility, and help provide a comprehensive view of the pharmacovigilance landscape. Participate: https://okt.to/BoFs4R

🎉 Join the Slogan Competition - 4th National Pharmacovigilance Week! 🎉 🗓 Date: 17th September 2024 🏆 Theme: "Safety First: Awareness on Reporting Adverse Events" Showcase your creativity and contribute to building a culture of Adverse Drug Reaction (ADR) reporting for patient safety! Submit your best slogan and stand a chance to be recognized. Competition Rules: 🖊 Open to all participants; one slogan per person 🖊 Slogan must relate to the theme: "Safety First: Awareness on Reporting Adverse Events" 🖊 Concise and original slogans, max 15 words 🖊 Submissions in English only 💡 Judging Criteria: Relevance to the Theme (40%) Creativity and Originality (30%) Clarity and Impact (30%) The top 3 slogans will be recognized! Don’t miss this opportunity to make your voice heard and support patient safety. Click the link to register now: https://lnkd.in/gcuDqzGq Let’s put #SafetyFirst and drive awareness on ADR reporting together! #PharmacovigilanceWeek2024 #SloganCompetition #PatientSafety #ADRReporting #ClinosolResearch #CreativityForSafety

The first comprehensive pharmacovigilance course in Alex.👓📚..check the course outlines📄...Subscribe now to benefit from the discount 📝💲

Are you struggling to manage a large volume of Adverse Event (AE) reports from the Canada Vigilance Adverse Reaction Database? Handling high volumes of AE reports with limited time and resources can be challenging and time consuming. That's why we've developed an innovative automated tool to help you streamline your processes, optimize resources, and consistently meet regulatory demands. Discover how Innomar’s pharmacovigilance team can support you with AE management: https://ow.ly/xny850Tj4ES

Are we asking the right questions? I was recently asked by a client "Do you think there will be major study implications with ongoing trials if we select a new Safety vendor now? Have you seen any major study implications from your experience".   For me, the more vital question is whether there will be major study implications with ongoing trials if you don’t select a new Safety vendor now. Typically when clients want to transition to a new PV group, it’s not because of small errors or a low level of frustration. There are usually giant gaping problems that need to be corrected for the good of the program and the safety of the patients, and the only solution available is to change to a new PV team. So, in answer to your question, yes, there will absolutely be major study implications with your ongoing trials if you select a new Safety vendor now! And if you select ProPharma, your narratives will be more robust, your medical coding will be more accurate, your frustration level will decrease, and then downstream your annual report will be cleaner and cases will close faster. It's your trial, it's your decision. We're here when you need us.

Successfully completed the course on Pharmacovigilance Basics - 1 from VigiServe Foundation!

Navigate the Pharmacovigilance landscape with confidence. Choose ProPharma for quality, efficiency, and compliance, tailored solutions, and a partnership built on understanding and proactive support. Discover how we redefine pharmacovigilance, treating every project as our only priority: https://lnkd.in/eXQF6-b5

📢 EMA Hosts Online Event for Launch of Revised GVP Module XVI & Addendum II   The European Medicines Agency (EMA) has recently published important updates to the following Good Pharmacovigilance Practice (GVP) documents: - GVP Annex I - Definitions (Rev 5) - GVP Module XVI – Risk Minimization Measures (Rev 3) - GVP Module XVI Addendum II – Methods for Evaluating Effectiveness of Risk Minimization Measures These updates are essential for anyone involved in regulatory and pharmacovigilance activities. To gain a deeper understanding of these changes, EMA is hosting a public online event on Wednesday, 11 September 2024, from 10:00 to 11:30 CEST. Register by September 10 at 12.00 CET via the following the link: https://lnkd.in/dAz_4njh. More information about the event can be found here.   ✨Stay effortlessly informed — Biocodex PhaMe’s RA-PV intelligence service ensures you’re updated on every important legislative change across the EU and in the Nordic and Baltic countries.

Skill development programme on Pharmacovilence